Brookmont Capital Management’s AstraZeneca AZN Stock Holding History

Brookmont Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.01M	Buy	26,436 +409	+2%	+$76.9K	2.69%	4
2026 Q1	$5.13M	Buy	26,027 +849	+3%	+$164K	2.87%	6
2025 Q4	$4.63M	Sell	25,178 -277	-1%	-$48.6K	2.68%	5
2025 Q3	$3.91M	Sell	25,455 -868	-3%	-$131K	2.17%	13
2025 Q2	$3.68M	Sell	26,323 -633	-2%	-$88.7K	2.11%	14
2025 Q1	$3.96M	Sell	26,956 -1,037	-4%	-$150K	2.24%	13
2024 Q4	$3.67M	Buy	27,993 +9,914	+55%	+$1.39M	1.96%	17
2024 Q3	$2.82M	Sell	18,079 -582	-3%	-$93.9K	1.45%	25
2024 Q2	$2.91M	Buy	+18,661	New	+$2.81M	1.59%	24

Other funds holding AZN

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

CDDEC

Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

BTCPP

Border to Coast Pensions Partnership Leeds, United Kingdom $6.78B AUM 31.6% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

ISS

Intesa Sanpaolo SpA. Turin, Italy $2.92B AUM

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Brookmont Capital Management's AZN Position: Q2 2026 in Review

Brookmont Capital Management increased its AstraZeneca (AZN) stake by 1.6% in Q2 2026, buying an estimated $76.9K and bringing the position to 26,436 shares worth $5.01M. The position accounts for 2.69% of the portfolio, ranked #4.

Brookmont Capital Management first reported a position in AZN in Q2 2024 and has held it in 9 quarters since. The position peaked at $5.13M in Q1 2026. 619 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Brookmont Capital Management held 26,436 shares of AstraZeneca worth $5.01M as of Q2 2026.
Brookmont Capital Management bought 409 AstraZeneca shares in Q2 2026, an estimated $76.9K.
AstraZeneca made up 2.69% of Brookmont Capital Management's portfolio in Q2 2026, its #4 holding.
Brookmont Capital Management first reported a position in AstraZeneca in Q2 2024 and has held it in 9 quarters since.
Brookmont Capital Management's AstraZeneca position peaked at $5.13M in Q1 2026.
619 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Brookmont Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.